WESTMINSTER RADAR
Search
My MPs
Menu

Question follow-through · 68687

Prostate Cancer: Hormone Treatments

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 July 2025 to Question 64682 on Prostate Cancer: Hormone Treatments, if his Department will publish the Equality and Health Inequalities Impact Assessment for abirateron

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
16 Jul 2025
Target answer date
21 Jul 2025
Answer
23 Jul 2025 · 7 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

More questions by this MP on Health and care

Shared topic keywords suggest a connection; they do not establish a follow-up.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 16 Jul 2025

    Question tabled

    To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 July 2025 to Question 64682 on Prostate Cancer: Hormone Treatments, if his Department will publish the Equality and Health Inequalities Impact Assessment for abirateron

  2. 21 Jul 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 23 Jul 2025

    Answer published

    The Equality and Health Inequalities Impact Assessment for abiraterone acetate plus prednisone for hormone-sensitive non-metastatic prostate cancer can be found in the attached document.

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Radiotherapy

18 Jul 2025 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a national radiotherapy advisory group.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Radiotherapy: Medical Equipment

18 Jul 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to include policies on replacing older radiotherapy machines in the national cancer plan.

Strong linkSame MP, department and exact heading

Prostate Cancer: Hormone Treatments

1 Sept 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question 64681 on Prostate Cancer: Hormone Treatments, for what reason recurrent headroom in revenue budgets is considered a barrier to implementing the abi

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Clinical Priorities Advisory Group

11 Sept 2025 · To ask the Secretary of State for Health and Social Care, whether the Clinical Priorities Advisory Group has a budget to approve new treatments.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Medical Treatments

10 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether there is a facility for the NHS to approve treatments without external payment for assessment by the National Institute for Health and Care Excellence.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Rare Cancers: Diagnosis

14 Oct 2025 · To ask the Secretary of State for Health and Social Care, how the full roll-out of the non-specific symptom pathways is being measured; and how their development has included the less survivable cancers.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Rare Cancers: Medical Treatments

14 Oct 2025 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of minimally invasive therapies for the less survivable cancers.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Abiraterone

17 Oct 2025 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of men in England with newly diagnosed high-risk, non-metastatic prostate cancer who would be eligible for abiraterone under the eligibility crit

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Abiraterone

17 Oct 2025 · To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential impact of prescribing abiraterone in England using the eligibility criteria used in (a) Scotland and (b) Wales on the number of premature deaths from hi

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Prostate Cancer: Abiraterone

17 Oct 2025 · To ask the Secretary of State for Health and Social Care, if he will make an estimate of the (a) cost per patient, (b) number of eligible patients, (c) net cost, (d) incremental quality-adjusted life years gained and (e) incremental cost-effectiveness rat

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Abiraterone

17 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether NHS England has approved any drugs with a higher incremental cost-effectiveness ratio than abiraterone for high-risk, non-metastatic prostate cancer in the last five years.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Abiraterone

17 Oct 2025 · To ask the Secretary of State for Health and Social Care, what information his Department holds on the estimate made by (a) NHS England, (b) NHS Wales and (c) NHS Scotland of the incremental cost-effectiveness ratio for abiraterone in high-risk, non-metas